Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + CR-001 + Paclitaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CR-001 | CR001|CR 001 | PD-L1/PD-1 antibody 139 VEGF Antibody 18 | CR-001 is a tetravalent bispecific antibody targeting PDCD1 (PD-1) and VEGF, which potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 1185). | |
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07335497 | Phase Ib/II | Cisplatin + CR-001 + Gemcitabine Capecitabine + CR-001 + Oxaliplatin CR-001 + Paclitaxel CR-001 + Fluorouracil + Leucovorin + Oxaliplatin CR-001 + Trifluridine-tipiracil hydrochloride Carboplatin + CR-001 + Paclitaxel CR-001 Carboplatin + CR-001 + Pemetrexed Disodium | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (ASCEND) | Recruiting | USA | ROU | ITA | IRL | GBR | FRA | ESP | AUS | 1 |